B. Braun obtains permanent injunction

Published: 5-May-2011
Regulatory

Prevails in case against Terumo Corporation for its Introcan Safety IV catheter patent


German medical device manufacturer B. Braun Melsungen AG and its US subsidiary B. Braun Medical Inc. have succeeded in obtaining a permanent injunction in the patent infringement case against Japan's Terumo Corporation and its US subsidiary Terumo Medical Corporation.

On 21 April 2011, the US District Court for the District of Delaware granted an immediate and permanent order stopping Terumo from selling, or offering to sell, the Surshield Safety IV catheter in the acute care market, precluding Terumo from bidding against B. Braun on expiring GPO contracts.

Terumo will be permitted to continue selling the Surshield Safety IV catheter into the alternative care market until 1 June 2012, after which it cannot make, sell, use or offer the Surshield Safety Catheter in the US. B. Braun will seek damages and other relief for Terumo's infringement.

B. Braun's win follows a previous verdict awarded in November 2010, confirming the validity of an infringed claim of B. Braun's 2007 patent (US Patent 7,264,613) for its Introcan Safety IV Catheter.

  • Companies:
  • B Braun Aseptic Consulting Service
See more

You may also like

Regulatory

B. Braun introduces WHIN Safe Huber Needle

Read more
Helps protect against needle-stick injuries, blood and fluid exposure

Trending Articles

  1. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  2. Overcoming CMC challenges in cell and gene therapy: part I Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  3. Overcoming CMC challenges in cell and gene therapy: part II Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  4. The rising importance of preservative efficacy testing When considering the regulation and validation of pharmaceutical products, the efficacy of the active pharmaceutical ingredient (API) is often the main concern
  5. The right validation model: practical considerations and applications It is widely accepted that validation in the life sciences industry follows a lifecycle model (1,2). What is not always clear is the specific model — or models — to follow and how to navigate through them in the real world. Hurdles to overcome include the specific deliverables that make up that model and how they change during the various interactions along the validation journey

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Regulatory

B. Braun introduces WHIN Safe Huber Needle

Helps protect against needle-stick injuries, blood and fluid exposure
Regulatory

Overcoming CMC challenges in cell and gene therapy: part II

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

Overcoming CMC challenges in cell and gene therapy: part I

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme

The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
Manufacturing

Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success

Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
Regulatory

Isospec Analytics launches biomolecular analysis technology to identify unknown molecules

The novel technology optimises the identification process of unknown molecules compared to mass analysis
Regulatory

4SC AG receives Paediatric Investigation Plan waiver for resminostat from the UK MHRA

The waiver allows the company to avoid investigating the CTCL drug in a paediatric population, as it's considered unnecessary or inappropriate for use by this patient group
Subscribe now